Human arylamine N-acetyltransferase 1: In vitro and intracellular inactivation by nitrosoarene metabolites of toxic and carcinogenic arylamines

Chemical Research in Toxicology

Volumn 21, Issue 10, 2008, Pages 2005-2016

  Liu, Li ^a   Wagner, Carston R ^a   Hanna, Patrick E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROSOFLUORENE; 2 NITROSOTOLUENE; 4 NITROSOBIPHENYL; ARYLAMINE ACETYLTRANSFERASE; GLUTATHIONE REDUCTASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NITROSO DERIVATIVE; NITROSOBENZENE; SULFINAMIDE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENSITOMETRY; DETOXIFICATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MASS SPECTROMETRY;

ACETYL COENZYME A; ACETYLCYSTEINE; AMINES; ARYLAMINE N-ACETYLTRANSFERASE; CARCINOGENS; CYTOSOL; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUTATHIONE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HELA CELLS; HUMANS; ISOENZYMES; KINETICS; MOLECULAR STRUCTURE; NITROGEN COMPOUNDS; RECOMBINANT PROTEINS;

EID: 55949129078     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx800215h     Document Type: Article

References (87)

1. Palmiotto, G., Pieraccini, G., Moneti, G., and Dolara, P. (2001) Determination of the levels of aromatic amines in indoor and outdoor air in Italy. Chemosphere 43, 355-361.
2. Richter, E., Rosler, S., Scherer, G., Gostomzyk, J. G., Grubl, A., Kramer, U., and Behrendt, H. (2001) Haemoglobin adducts from aromatic amines in children in relation to area of residence and exposure to environmental tobacco smoke. Int. Arch. Occup, Environ. Health 74, 421-428.
3. DeBruin, L. S., Pawliszyn, J. B.and., and Josephy, P. D. (1999) Detection of monocyclic aromatic amines, possible mammary carcinogens, in human milk. Chem. Res. Toxicol. 12, 78-82.
4. Parkes, H. G., and Evans, A. E. J. (1984) Epidemiology of aromatic amine cancers. In Chemical Carcinogens, 2nd ed. (Searle, C. E., Ed.) Vol. 1, pp 277-301, American Chemical Society, Washington, DC.
5. Garner, R. C., Martin, C. N., and Clayson, D. B. (1984) Carcinogenic aromatic amines and related compounds. In Chemcal Carcinogens, 2nd ed. (Searle, C. E., Ed.) Vol. 1, pp 175-276, American Chemical Society, Washington, DC.
6. Miller, J. A. (1998) The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: A collaboration with Elizabeth Cavert Miller and our associates. Drug. Metab. Rev. 30, 645-674.
7. Hanna, P. E. (1996) Metabolic activation and detoxification of arylamines. Curr. Med. Chem. 3, 195-210.
8. Cohen, S. M., Boobis, A. R., Meek, M. E., Preston, R. J., and McGregor, D. B. (2006) 4-Aminobiphenyl and DNA reactivity: Case study within the context of the 2006 IPCS Human Relevance Framework for Analysis of a cancer mode of action for humans. Crit. Rev. Toxicol. 36, 803-819.
9. Skipper, P. L., Tannenbaum, S. R., Ross, R. K., and Yu, M. C. (2003) Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer. Epidemiol. Biomarkers Prev. 12, 503-507.
10. Gan, J., Skipper, P. L., Gago.Dominquez, M., Arakawa, K., Ross, R. K., Yu, M. C., and Tannenbaum, S. R. (2004) Alkylaniline-hemoglobin adducts and risk of non-smoking related bladder cancer. J. Nail. Cancer Inst. 96, 1425-1431.
11. Airoldi, L., Orsi, F., Magagnotti, C., Coda, R., Randone, D., Casetta, G., Peluso, M., Hautefeuille, A., Malaveille, C., and Vineis, P. (2002) Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies. Carcinogenesis 23, 861-866.
12. Zayas, B., Stillwell, S. W., Wishnok, J. S., Trudel, L. J., Skipper, P., Yu, M. C., Tannenbaum, S. R., and Wogan, G. N. (2007) Detection and quantification of 4-ABP adducts in DNA from bladder cancer patients. Carcinogenesis 28, 342-349.
13. Patrianakos, C., and Hoffman, D. (1979) Chemical studies on tobacco smoke LXIV. On the analysis of aromatic amines in tobacco smoke. J. Anal. Toxicol. 3, 150-154.
14. Smith, C. J., Dooly, G. L., and Moldoveanu, S. C. (2003) New technique using solid-phase extraction for the analysis of aromatic amines in mainstream cigarette smoke. J. Chromatogr. A 991, 99-107.
15. Mommsen, S., and Aagaard, J. (1983) Tobacco as a risk factor in bladder cancer. Carcinogenesis 4, 335-338.
16. Bryant, M. S., Skipper, P. L., Tannenbaum, S. R., and Maclure, M. (1987) Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers. Cancer Res. 47, 602-608.
17. Sarkar, M., Stabbert, R., Kinser, R. D., Oey, J., Rustemeier, K., von.Holt, K., Schepers, G., Walk, R. A., and Roethig, H. J. (2006) CYP1A2 and NAT2 phenotyping and 3-aminobiphenyl and 4-aminobiphenyl hemoglobin adduct levels in smokers and non-smokers. Toxicol. Appl. Pharmacol. 213, 198-206.
18. Kim, D., and Guengerich, F. P. (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu. Rev, Pharmacol. Toxicol. 45, 27-49.
19. Beland, F. A., and Kadlubar, F. F. (1990) Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons. Handbook Exp. Pharmacol. 94/1, 267-325.
20. Grantham, P. H., Weisburger, E. K., and Weisburger, J. H. (1965) Dehydroxylation and deacetylation of N-hydroxy-N-2- fluorenylacetamide by rat liver and brain homogenates. Biochim. Biophys. Acta 107, 414-424.
21. Mulder, G. J., Unruh, L. E., Evans, F. E., Ketterer, B., and Kadlubar, F. F. (1982) Formation and identification of glutathione conjugates from 2-nitrosofluorene and N-hydroxy-2-aminofluorene. Chem.-Biol. Interact. 39, 111-127.
22. Eyer, P. (1994) Reactions of oxidatively activated arylamines with thiols: reaction mechanisms and biologic implications. An overview. Environ. Health Perspect. 102 (S6), 123-132.
23. Kazanis, S., and McClelland, R. A. (1992) Electrophilic intermediate in the reaction of glutathione and nitrosoarenes. J. Am. Chem. Soc. 114, 3052-3059.
24. Skipper, P. L., and Stillwell, W. G. (1994) Aromatic amine-hemoglobin adducts. Methods Enzymol. 231, 643-649.
25. Josephy, P. D., and Mannervik, B. (2006) Molecular Toxicology, 2nd ed., pp 426-447, Oxford University Press, New York.
26. Hanna, P. E. (1994) N-Acetyltransferases, O- acetyltransferases and N,O-acetyltransferases: Enzymology and bioactivation. Adv. Pharmacol. 27, 401-430.
27. Hein, D. W. (2006) N-Acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25, 1649-1658.
28. Meisel, P. (2002) Arylamine N-acetyltransferases and drug response. Pharmacogenomics 3, 349-366.
29. Minchin, R. F., Hanna, P. E., Dupret, J. M., Wagner, C. R., Rodrigues-Lima, F.and., and Butcher, N. J. (2007) Arylamine N- acetyltransferase I. Int. J. Biochem. Cell Biol. 39, 1999-2005.
30. Sim, E., Westwood, I., and Fullam, E. (2007) Arylamine N-acetyl-transferases. Expert Opin, Drug Metab. Toxicol. 3, 169-184.
31. Walraven, J. M., Trent, J. O., and Hein, D. W. (2008) Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1. Drug Metab. Rev. 40, 169-184.
32. Dupret, J. M., and Rodrigues-Lima, F. (2005) Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Curr. Med. Chem. 12, 311-318.
33. Hanna, P. E., Banks, R. B., and Marhevka, V. C. (1982) Suicide inactivation of hamster hepatic arylhydroxamic acid N,O-acyltrans-ferase. A selective probe of N-acetyltransferase multiplicity. Mol. Pharmacol. 21, 159-165.
34. Wick, M. J., and Hanna, P. E. (1990) Bioactivation of N-arylhydroxamic acids by rat hepatic N-acetyltransferase. Detection of multiple enzyme forms by mechanism based inactivation. Biochem. Pharmacol. 39, 991-1003.
35. Sticha, K. R. K., Bergstrom, C. P., Wagner, C. R., and Hanna, P. E. (1998) Characterization of hamster recombinant monomorphic and polymorphic arylamine W-acetyltransferases. Bioactivation and mechanism based inactivation studies with N-hydroxy-2-acetylaminofluo-rene. Biochem. Pharmacol. 56, 47-59.
36. Smith, T. J., and Hanna, P. E. (1988) Hepatic N- acetyltransferases: Selective inactivation in vivo by a carcinogenic N-arylhydroxamic acid. Biochem. Pharmacol. 37, 427-434.
37. Guo, Z., Wagner, C. R., and Hanna, P. E. (2004) Mass spectrometric investigation of the mechanism of inactivation of hamster arylamine N-acetyltransferase 1 by N-hydroxy-2-acetylaminofluorene. Chem. Res. Toxicol. 17, 275-286.
38. Wang, H., Wagner, C. R., and Hanna, P. E. (2005) Irreversible inactivation of arylamine N-acetyltransferases in the presence of N-hydroxy-4-acetylaminobiphenyl: A comparison of human and hamster enzymes. Chem. Res. Toxicol. 18, 183-197.
39. Liu, L., Von Vert, A., Zhang, N., Walters, K. J., Wagner, C. R., and Hanna, P. E. (2007) Arylamine N-acetyltranserases: Characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2. Chem. Res. Toxicol. 20, 1300-1308.
40. NIH (1981) NIH Guidelines for the Laboratory Use of Chemical Carcinogens, NIH Publication No. 81-2385, U.S. Government Printing Office, Washington, DC.
41. Wang, H., Vath, G. M., Kawamura, A., Bates, C. A., Sim, E., Hanna, P. E., and Wagner, C. R. (2005) Overexpression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. Protein J. 24, 65-77.
42. Stanley, L. A., Coroneos, E., Cuff, R., Hickman, D., Ward, A., and Sim, E. (1996) Immunochemical detection of arylamine N-acetyl-transferase in normal and neoplastic bladder. J. Histochem. Cytochem. 44, 1059-1067.
43. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
44. Sinclair, J. C., Delgoda, R., Noble, M. E., Jarmin, S., Goh, N. K., and, and Sim, E. (1998) Purification, characterization, and crystallization of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium. Protein Expression Purif. 12, 371-380.
45. McAlister, L., and Holland, M. J. (1985) Differential expression of the three yeast glyceraldehyde-3-phosphate dehydrogenase genes. J. Biol. Chem. 260, 15019-15027.
46. Cohen, M. B., and Duvel, D. L. (1988) Characterization of the inhibition of glutathione reductase and the recovery of enzyme activity in exponentially growing murine leukemia (L1210) cells treated with 1,3-bis(2-chloroethyl)-1- nitrosourea. Biochem. Pharmacol. 37, 3317-3320.
47. Goswami, P. C., Sheren, J., Albee, L. D., Parsian, A., Sim, J. E., Ridnour, L. A., Higashikubo, R., Gius, D., Hunt, D. R., and Spitz, D. R. (2000) Cell cycle-coupled variation in topoisomerase IIα mRNA is regulated by the 3′-untranslated region. J. Biol. Chem. 275, 38384-38392.
48. Liu, F., Zhang, N., Zhou, X., Hanna, P. E., Wagner, C. R., Koepp, D. M., and Walters, K. J. (2006) Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J. Mol. Biol. 361, 482-492.
49. Kitz, R., and Wilson, I. B. (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 237, 3245-3249.
50. Levy, H. M., Leber, P. D., and Ryan, E. M. (1963) Inactivation of myosin by 2, 4-dinitrophenol and protection by adenosine triphosphate and other phosphate compounds. J. Biol. Chem. 238, 3654-3659.
51. Lotlikar, P. D., Miller, E. C., Miller, J. A., and Margreth, A. (1965) The enzymatic reduction of the N-hydroxy derivatives of 2-acety-laminofluorene and related carcinogens by tissue preparations. Cancer Res. 25, 1743-1751.
52. Eyer, P. (1979) Reactions of nitrosobenzene with reduced glutathione. Chem,-Biol. Interact. 24, 227-239.
53. Dolle, B., Topner, W., and Neumann, H.-G. (1980) Reaction of arylnitroso compounds with mercaptans. Xenobiotica 10, 527-536.
54. Butcher, N. J., Tetlow, N. L., Cheung, C., Broadhurst, G. M., and Minchin, R. F. (2007) Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res. 67, 85-92.
55. Grant, D. M., Lottspeich, F., and Meyer, U. A. (1989) Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett. 244, 203-207.
56. Nakano, M., Funayama, S., de Oliveira, M. B. M., Sung, L. B., and Gomes, E. M. (1992) D-Glyceraldehyde-3-phosphate dehydrogenase from HeLa cells. 1. Purification and properties of the enzyme. Comp. Biochem. Physiol, Part B: Biochem. Mol. Biol. 102, 873-877.
57. Dietze, E. C., Schafer, A., Omichinski, J. G., and Nelson, S. D. (1997) Inactivation of glyceraldehyde-3-phosphate dehydrogenase by a reactive metabolite of acetaminophen and mass spectral characterization of an arylated active site peptide. Chem. Res. Toxicol. 10, 1097-1103.
58. Dennehy, M. K., Richards, K. A. M., Wernke, G. R., Shyr, Y., and Liebler, D. C. (2006) Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem. Res. Toxicol. 19, 20-29.
59. Pai, E. F., and Schulz, G. E. (1983) The catalytic mechanism of glutathione reductase as derived from x-ray diffraction analyses of reaction intermediates. J. Biol. Chem. 258, 1752-1757.
60. Babson, J. R., and Reed, D. J. (1978) Inactivation of glutathione reductase by 2-chloroethyl nitrosourea-derived isocyanates. Biochem. Biophys. Res. Commun. 83, 754-762.
61. Karplus, P. A., Krauth-Siegel, R. L., Schirmer, R. H., and Schulz, G. E. (1988) Inhibition of human glutathione reductase by the nitrosourea drugs 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1- nitrosourea. Eur. J. Biochem. 171, 193-198.
62. Butcher, N. J., Ilett, K. F., and Minchin, R. F. (2000) Inactivation of human arylamine N-acetyltransferase 1 by the hydroxylamine of p-aminobenzoic acid. Biochem. Pharmacol. 60, 1829-1836.
63. Hao, X-Y., Widersten, M., Ridderström, M., Hellman, U., and Mannervik, B. (1994) Co-variation of glutathione transferase expression and cytostatic drug resistance in HeLa cells: Establishment of class Mu glutathione transferase M3-3 as the dominating isoenzyme. Biochem. J. 297, 59-67.
64. Lu, S. C., Sun, W.-M., Yi, J., Ookhtens, M., Sze, G., and Kaplowitz, N. (1996) Role of two recently cloned rat liver GSH transporters in the ubiquitous transport of GSH in mammalian cells. J. Clin. Invest. 97, 1488-1496.
65. Menon, S. G., Coleman, M. C., Walsh, S. A., Spitz, D. R., and Goswami, P. C. (2005) Differential susceptibility of nonmalignant human breast epithelial cells and breast cancer cells to thiol antioxidant-induced G,-delay. Antioxid. Redox Signaling 7, 711-718.
66. Weber, W. W., and Hein, D. W. (1985) N-Acetylation pharmacogenetics. Pharmacol. Rev. 37, 26-79.
67. Evans, D. A. P. (1989) N-Acetyltransferase. Pharmacol. Ther. 42, 157-234.
68. Atmane, N., Dairou, J., Paul, A., Dupret, J.-M., and Rodrigues-Lima, F. (2003) Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1). J. Biol. Chem. 278, 35086-35092.
69. Dairou, J., Malecaze, F., Dupret, J.-M., and Rodrigues-Lima, F. (2005) The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: Inactivation by cellular oxidants and UVB-induced oxidative stress. Mol. Pharmacol. 67, 1299-1306.
70. Dairou, J., Atmane, N., Rodrigues.Lima, F., and Dupret, J.-M. (2004) Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells. J. Biol. Chem. 279, 7708-7714.
71. Dairou, J., Dupret, J.-M., and Rodrigues-Lima, F. (2005) Impairment of the activity of the xenobiotic-metabolizing enzymes arylamine N-acetyltransferases 1 and 2 (NAT1/NAT2) by peroxynitrite in mouse skeletal muscle cells. FEBS Lett. 579, 4719-4723.
72. King, R. S., and Duffel, M. W. (1997) Oxidation-dependent inactivation of aryl sulfotransferase IV by primary N-hydroxy arylamines during in vitro assays. Carcinogenesis 18, 843-849.
73. Ragunathan, N., Dairou, J., Pluvinage, B., Martins, M., Petit, E., Janel, N., Dupret, J.-M., and Rodrigues-Lima, F. (2008) Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition. Mol. Pharmacol. 73, 1761-1768.
74. Szabo, C., Ischiropoulos, H., and Radi, R. (2007) Peroxynitrite: Biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discovery 6, 662-680.
75. Jatoe, S. D., Khan, S., and O'Brien, P. J. (1991) Molecular cytotoxic mechanism of carcinognic arylamines. Prog. Pharmacol. Clin. Pharmacol. 8, 245-253.
76. Neumann, H.-G. (2007) Aromatic amines in experimental cancer research: Tissue-specific effects, an old problem and new solutions. Crit. Rev. Toxicol. 37, 211-236.
77. Floyd, R. A., Soong, L. M., Stuart, M. A., and Reigh, D. L. (1978) Free radicals and carcinogenesis. Some properties of the nitroxyl free radicals produced by covalent binding of 2-nitrosofluorene to unsaturated lipids of membranes. Arch. Biochem. Biophys. 185, 450-457.
78. Naisbitt, D. J., Farrell, J., Gordon, S. F., Maggs, J. L., Burkhart, C., Pichler, W. J., Pirmohamed, M., and Park, B. K. (2002) Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol. Pharmacol. 62, 628-637.
79. Vyas, P. M., Roychowdhury, S., Koukouritaki, S. B., Hines, R. N., Krueger, S. K., Williams, D. E., Nauseef, W. M., and Svensson, C. K. (2006) Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: II. Expression and role of flavin-containing monooxygenases and peroxidases. J. Pharmacol. Exp. Ther. 319, 497-505.
80. Zhang, N., Liu, L., Liu, F., Wagner, C. R., Hanna, P. E., and Walters, K. J. (2006) NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity. J. Mol. Biol. 363, 188-200.
81. Wu, H., Dombrovsky, L., Tempel, W., Martin, F., Loppnau, P., Goodfellow, G. H., Grant, D. M., and Plotnikov, A. N. (2007) Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J. Biol. Chem. 282, 30189-30197.
82. Wang, H., Vath, G. M., Gleason, K. J., Hanna, P. E., and Wagner, C. R. (2004) Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies. Biochemistry 43, 8234-8246.
83. Beije, B., and Moller, L. (1988) 2-Nitrofluorene and related compounds: Prevalence and biological effects. Mutat. Res. 196, 177-209.
84. Zwirner-Baier, I., and Neumann, H.-G. (1999) Polycyclic nitroarenes (nitro-PAHs) as biomarkers of exposure to diesel exhaust. Mutat. Res. 441, 135-144.
85. Boelsterli, U. A., Ho, H. K., Zhou, S., and Leow, K. Y. (2006) Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr. Drug Metab. 7, 715-727.
86. Adam, P. J., Berry, J., Loader, J. A., Tyson, K. L., Craggs, G., Smith, P., De.Belin, J., Steers, G., Pezzella, F., Sachsenmeir, K. R, Stamps, A. C., Herath, A., Sim, E., O'Hare, M. J., Harris, A. L., and Terrett, J. A. (2003) Arylamine N-acetyltransferase-l is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol. Cancer Res. 1, 826-835.
87. Sim, E., Pinter, K., Mushtaq, A., Upton, A., Sandy, J., Bhakta, S., and Noble, M. (2003) Arylamine N-acetyltransferases: A pharmacogenomic approach to drug metabolism and endogenous function. Biochem. Soc. Trans. 31, 615-619.